Ulcerative colitis is a chronic inflammatory bowel disease in which the immune system attacks the lining of the large intestine, causing continuous stretches of inflammation that typically begin at the rectum and can extend upward through the entire colon. Unlike passing stomach bugs or food intolerances, the inflammation in ulcerative colitis is relapsing and lifelong, driven by a combination of genetic susceptibility, immune dysfunction, and environmental triggers that researchers are still working to untangle. The condition affects millions worldwide, and its incidence has been climbing sharply in regions where it was once rare.
What Drives the Disease
Ulcerative colitis does not have a single cause. It arises from a collision of genetic predisposition, a misfiring immune system, disrupted gut bacteria, and environmental exposures. The genetic side involves dozens of gene variants, many of which affect how the body produces and responds to inflammatory signaling molecules called cytokines. Polymorphisms in genes for interleukins and their receptors appear to play a central role in amplifying gut inflammation.1PubMed Central. Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature
On the immune side, the inflammation is orchestrated by an imbalance of cytokines produced by both innate and adaptive immune cells. Macrophages in the gut wall ramp up production of inflammatory molecules, and different types of T-helper cells push the inflammation in various directions depending on the stage of disease.2PubMed Central. Role of cytokines in inflammatory bowel disease The cytokine profile is not static: levels of molecules like IL-1β, IL-6, and tumor necrosis factor-α shift depending on whether the disease is flaring or smoldering, and they vary from patient to patient.3PubMed. The influence of cytokines on the complex pathology of ulcerative colitis That variability is one reason why a treatment that works brilliantly for one person may do nothing for another.
The gut’s physical barrier also breaks down. Mucins, the glycosylated proteins that form the protective mucus layer over the intestinal lining, are altered in ulcerative colitis patients. When that mucus shield thins or changes composition, bacteria can reach the delicate epithelial cells underneath and provoke further immune attack.4PubMed Central. The Relationship between Mucins and Ulcerative Colitis: A Systematic Review Meanwhile, the microbial community itself shifts. Patients tend to lose beneficial, butyrate-producing bacteria and gain species associated with inflammation.5Scientific Reports. Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study Whether the dysbiosis causes the disease or the disease causes the dysbiosis remains a chicken-and-egg question, but it is likely a self-reinforcing cycle.
The Curious Roles of Smoking and the Appendix
Few findings in gastroenterology are as counterintuitive as the relationship between smoking and ulcerative colitis. While smoking is devastating for almost every other organ system, it appears to be protective against this particular disease. In one case-control study, current smokers had roughly half the odds of developing ulcerative colitis compared to people who had never smoked or had quit.6PubMed. Appendectomy, smoking habits and the risk of developing ulcerative colitis: a case control study in private practice setting Former smokers, in fact, seem to be at higher risk than those who never picked up the habit, and many gastroenterologists have noticed that patients often develop their first flare shortly after quitting. To be clear, nobody recommends smoking as therapy. The harms far outweigh the narrow benefit. But the observation has pushed researchers toward nicotine patches and other nicotinic-receptor-targeting approaches as potential treatments.
Prior appendectomy is similarly protective. In the same study, only about 12% of ulcerative colitis patients had previously had their appendix removed, compared to 46% of matched controls, translating to dramatically lower odds of developing the disease.7PubMed. Appendectomy, smoking habits and the risk of developing ulcerative colitis: a case control study in private practice setting And for those who already have the disease, having had an appendectomy and being a current smoker were both independently associated with a lower chance of eventually needing the colon removed.8PubMed Central. Effects of appendicectomy on the course of ulcerative colitis The mechanism is not fully understood, but the appendix is rich in immune tissue and may act as a priming site for the type of immune response that fuels colonic inflammation.
How It Is Diagnosed
Diagnosis starts with symptoms: bloody diarrhea, urgency, abdominal cramping, and sometimes weight loss or fever. But confirming ulcerative colitis requires looking at the colon directly with a colonoscopy and taking tissue biopsies. The pattern of inflammation is key: ulcerative colitis produces continuous inflammation starting at the rectum, whereas Crohn’s disease can appear in patches anywhere from mouth to anus.
Between colonoscopies, doctors increasingly rely on fecal calprotectin, a protein released by inflamed intestinal tissue, as a non-invasive way to monitor disease activity. Calprotectin levels correlate strongly with what a colonoscopy would show. One study found that a calprotectin cutoff of about 60 micrograms per gram of stool could distinguish a completely healed colon from one with any residual inflammation with high accuracy.9PubMed. Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis Higher cutoffs detect more severe inflammation: around 110 micrograms per gram separates mild from moderate-to-severe disease, and values above 300 suggest severe inflammation.10PubMed. Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis Other research using different assays has confirmed that calprotectin rises in a roughly linear fashion as disease activity worsens.11PubMed Central. The value of fecal calprotectin measured by fluorescent immunochromatography assay in evaluating clinical and endoscopic activity in ulcerative colitis For patients, this means a simple stool test can often flag a flare before symptoms become obvious, allowing earlier intervention.
The Treatment Ladder
Treatment follows a stepwise approach. The first rung for mild-to-moderate disease is mesalamine (also called mesalazine or 5-ASA), an anti-inflammatory drug that works directly on the inflamed colon lining. Response rates in active disease range from about 40% to 70%, with remission rates of roughly 15% to 20%.12PubMed Central. The role of mesalamine in the treatment of ulcerative colitis Higher doses perform better than lower ones for active flares, and combining oral and rectal formulations (enemas or suppositories) tends to outperform either alone. Because the drug acts locally rather than systemically, side effects are mild for most people.13PubMed Central. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?
When mesalamine is not enough, corticosteroids are the standard rescue therapy for moderate-to-severe flares. They work fast but come with well-known baggage: bone thinning, weight gain, mood swings, blood-sugar disruption. In severe disease, steroids achieve remission in roughly half of patients.14PubMed Central. Severe ulcerative colitis: at what point should we define resistance to steroids? The other half either do not respond at all or become steroid-dependent, meaning the disease flares every time the dose is tapered. Recent laboratory work has identified a protein called Twist1 that physically blocks the steroid receptor in immune cells, preventing the drug from doing its job. In experimental models, silencing Twist1 restored steroid sensitivity, offering a possible future target for patients trapped in steroid resistance.15PubMed Central. Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis
Biologics and Small Molecules
For patients who fail mesalamine and cannot get off steroids, biologic therapies are the next step. The longest-established class targets tumor necrosis factor-α (anti-TNF agents like infliximab and adalimumab). A meta-analysis found that anti-TNF drugs and anti-integrin drugs (like vedolizumab) induced mucosal healing in about 45% of patients, compared to 30% on placebo.16PubMed Central. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials In real-world practice, a long-term retrospective study showed that about 63% of patients on infliximab and 57% on adalimumab responded, with infliximab showing the longest average time before patients needed to switch to a different drug.17PubMed Central. Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
Vedolizumab, which targets gut-specific immune trafficking rather than systemic inflammation, has an interesting trajectory. Early remission rates look modest, but a two-year observational study found that vedolizumab-treated patients achieved significantly higher clinical remission at the two-year mark compared to anti-TNF-treated patients (about 43% versus 26%), and far fewer needed to switch therapies.18PubMed. Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis The trade-off is patience: vedolizumab is a slow burner that rewards sticking with it.
A newer wave of oral small-molecule drugs is reshaping treatment. JAK inhibitors (tofacitinib, filgotinib, upadacitinib) and sphingosine-1-phosphate receptor modulators (ozanimod, etrasimod) all work for ulcerative colitis. Their advantages over biologics include oral dosing, no risk of developing antibodies against the drug, and faster onset of action. The trade-offs are different: JAK inhibitors require lipid monitoring because they can raise cholesterol, and the S1P modulators carry a small risk of slowed heart rate at the first dose and, in susceptible individuals, eye problems.19PubMed. The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease
When Surgery Becomes Necessary
About 10% to 15% of ulcerative colitis patients eventually need surgery, typically because the disease stops responding to medications or because precancerous changes are found. The standard procedure is removal of the entire colon and rectum, followed by construction of an internal pouch from the small intestine (called a J-pouch) that is connected to the anus. This eliminates the disease-affected organ while preserving the ability to pass stool without a permanent external bag.20PubMed Central. Complications Related to J-Pouch Surgery
Surgery is not without consequences. Up to 70% of patients develop pouchitis, an inflammation of the newly created pouch, at some point after the procedure.21PubMed Central. Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment Most cases respond to antibiotics, but about 10% of patients with pouchitis eventually need the pouch removed entirely. A subset of patients even develops a Crohn’s-like condition of the pouch, which is the most common reason for complete pouch failure.22PubMed Central. Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment Timing matters too: patients who undergo urgent surgery tend to be sicker, more malnourished, and on higher steroid doses. They face more short-term complications, and inexperienced surgeons performing these operations are associated with substantially higher odds of long-term problems like fistulas and pouch failure.23The American Journal of Surgery. Impact of urgent surgery on outcomes in ulcerative colitis patients
Colorectal Cancer Risk
Long-standing ulcerative colitis raises the risk of colorectal cancer, particularly when inflammation involves at least a third of the colon. The risk begins to climb meaningfully after about eight to ten years of disease. The good news is that improved treatments and better surveillance programs have brought cancer incidence down over recent decades.24PubMed Central. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments
Current guidelines recommend regular surveillance colonoscopies, increasingly using chromoendoscopy, a technique where dye is sprayed on the colon surface to make precancerous changes more visible. Most dysplastic lesions in ulcerative colitis patients turn out to be visible with modern high-definition scopes, shifting the approach from taking random biopsies everywhere to targeting visible abnormalities.25PubMed Central. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments Colonoscopic features also help stratify risk. If the colon looks normal on colonoscopy, the five-year cancer risk drops back to that of the general population, and some experts argue surveillance intervals can be extended to every five years in those patients. Conversely, strictures found during colonoscopy carry substantially higher cancer risk, and post-inflammatory polyps also signal an elevated likelihood of future problems.26Gut. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk
Beyond the Gut
Ulcerative colitis is not solely a bowel disease. Up to a quarter or more of patients develop extraintestinal manifestations, symptoms that affect organs far from the colon. The most common involve joints (inflammatory arthritis affecting the spine or peripheral joints), skin (erythema nodosum, painful red nodules usually on the shins; or pyoderma gangrenosum, deep ulcerating sores), and eyes (uveitis or episcleritis causing redness and pain).27PubMed Central. Extraintestinal manifestations of inflammatory bowel disease Some of these track with intestinal inflammation and improve when the bowel quiets down. Others, like primary sclerosing cholangitis, a progressive scarring of the bile ducts, march to their own drum and can worsen independently of gut disease activity.28PubMed Central. Extraintestinal manifestations in inflammatory bowel disease Recognizing that virtually any organ system can be involved is important because patients sometimes see a dermatologist or rheumatologist for years before anyone connects their symptoms to their bowel disease.
The Brain-Gut Connection
Stress does not cause ulcerative colitis, but it unambiguously makes it worse. Chronic psychological stress is recognized as a trigger for disease flares and relapses. The relationship runs in both directions: active bowel inflammation increases inflammatory signaling in the central nervous system, which in turn drives higher rates of anxiety and depression, which further disrupts immune regulation in the gut.29PubMed Central. Psychological stress in inflammatory bowel disease: Psychoneuroimmunological insights into bidirectional gut-brain communications This bidirectional loop means that mental health treatment is not a luxury add-on for ulcerative colitis patients. Cognitive behavioral therapy, clinical psychology support, and sometimes psychiatric medication can break the cycle and reduce flare frequency independently of changes to gut-targeted medications.
Ulcerative Colitis in Children
Pediatric-onset ulcerative colitis tends to be more aggressive than the adult form. Children, especially those diagnosed before age eight, more often present with pancolitis (inflammation of the entire colon) rather than limited disease. In one pediatric cohort, about a third had pancolitis at diagnosis and another 15% had extensive disease, meaning most young patients started with widespread inflammation.30PubMed. Presenting features and disease course of pediatric ulcerative colitis Pediatric treatment strategies must account for growth, puberty, bone development, and the psychological impact of chronic illness during formative years, all of which make aggressive disease control especially urgent.31Journal of Crohn’s and Colitis. Differences in the management of pediatric and adult onset ulcerative colitis
Fecal Microbiota Transplantation
Given the role of gut bacteria in the disease, transplanting a healthy person’s stool microbiota into a patient with ulcerative colitis has been a tantalizing research avenue. The data are genuinely encouraging, though still early. A meta-analysis of randomized controlled trials found that fecal microbiota transplantation (FMT) roughly doubled the odds of achieving combined clinical and endoscopic remission compared to placebo.32PubMed Central. Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials A separate meta-analysis confirmed these findings and found no significant difference in adverse events between FMT and control groups.33Scientific Reports. Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis
One well-designed randomized trial delivered donor stool via colonoscopy and found that about 32% of patients achieved steroid-free remission at eight weeks, compared to 9% receiving their own (autologous) stool as a control. The clinical response rate was even higher at 55% versus 23%.34JAMA. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial The catch is durability: only about 42% of those initial responders maintained remission at twelve months.35JAMA. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial FMT is not yet standard therapy for ulcerative colitis, but the signal is strong enough that larger, longer trials are underway.
Diet, Short-Chain Fatty Acids, and Practical Nutrition
No diet cures ulcerative colitis, but what you eat influences the gut environment in ways that matter. Dietary fiber is fermented by gut bacteria into short-chain fatty acids, particularly butyrate, which serves as the primary energy source for colon lining cells and has anti-inflammatory properties. Patients with active disease tend to have lower levels of these beneficial metabolites.36PubMed Central. Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease A randomized, placebo-controlled trial tested supplemental sodium butyrate in patients with active ulcerative colitis and found that calprotectin levels (a direct measure of intestinal inflammation) dropped substantially in the butyrate group while rising in the placebo group. The supplement also lowered a systemic inflammation marker.37PubMed Central. Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial
During flares, many patients instinctively avoid fiber because raw vegetables and whole grains can worsen cramping and diarrhea. This is reasonable in the short term but creates a long-term paradox: the colon needs the byproducts of fiber fermentation to heal. Working with a dietitian to find tolerable fiber sources during remission, or considering butyrate supplementation during flares, is a conversation worth having with your gastroenterologist.
Pregnancy and Ulcerative Colitis
One of the most common anxieties for patients of reproductive age is whether it is safe to become pregnant while on ulcerative colitis medications. The evidence is clear that active disease during pregnancy poses a greater risk to both mother and baby than most maintenance medications do. Stopping treatment out of fear of drug effects often leads to flares, and those flares are associated with worse pregnancy outcomes.38PubMed. Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes Mesalamine and most biologics are considered compatible with pregnancy by major gastroenterology societies. Methotrexate is a clear exception and must be stopped well before conception. The ideal scenario is achieving stable remission before becoming pregnant and maintaining medication throughout. Pre-conception counseling with both a gastroenterologist and an obstetrician can tailor the plan to the specific drugs a patient uses.
A Global Disease on the Rise
Ulcerative colitis was historically concentrated in North America, northern Europe, and Australia. Over the past four decades, that picture has changed dramatically. Incidence and prevalence have climbed between roughly 1.5-fold and nearly 20-fold in parts of Asia, though overall rates remain lower than in the West.39Taylor & Francis Online (Expert Review of Gastroenterology & Hepatology). Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia The speed of this increase points strongly toward environmental and lifestyle factors, since genetic pools do not shift that fast. Urbanization, dietary westernization, improved sanitation (which may paradoxically reduce early microbial exposures), antibiotic overuse, and changes in physical activity have all been proposed as contributors. For healthcare systems in newly affected regions, the challenge is building the specialist infrastructure and drug access that patients in Western countries have had decades to develop.